# A Feasibility Study for Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in ELM Gastric Cancer

> **NCT03258034** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital of Zhejiang Chinese Medical University** · enrollment: 50 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** SPA

## Key facts

- **NCT ID:** NCT03258034
- **Lead sponsor:** The First Affiliated Hospital of Zhejiang Chinese Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-08-24
- **Primary completion:** 2020-08-22
- **Final completion:** 2021-10-22
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2017-08-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03258034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03258034, "A Feasibility Study for Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in ELM Gastric Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03258034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*